Your browser doesn't support javascript.
loading
Impact of safety-net hospital burden on achievement of textbook oncologic outcomes following resection in for stage I-IV colorectal cancer.
Wong, Paul; Victorino, Gregory P; Miraflor, Emily; Alseidi, Adnan; Maker, Ajay V; Thornblade, Lucas W.
Afiliação
  • Wong P; Division of Surgical Oncology, Department of Surgery, University of California, San Francisco, San Francisco, California, USA.
  • Victorino GP; Department of Surgery, UCSF-East Bay Program, Highland Hospital, Oakland, California, USA.
  • Miraflor E; Department of Surgery, UCSF-East Bay Program, Highland Hospital, Oakland, California, USA.
  • Alseidi A; Division of Surgical Oncology, Department of Surgery, University of California, San Francisco, San Francisco, California, USA.
  • Maker AV; Division of Surgical Oncology, Department of Surgery, University of California, San Francisco, San Francisco, California, USA.
  • Thornblade LW; Division of Surgical Oncology, Department of Surgery, University of California, San Francisco, San Francisco, California, USA.
J Surg Oncol ; 129(2): 284-296, 2024 Feb.
Article em En | MEDLINE | ID: mdl-37815003
ABSTRACT
BACKGROUND AND

OBJECTIVES:

Textbook oncologic outcome (TOO) is a benchmark for high-quality surgical cancer care but has not been studied at safety-net hospitals (SNH). The study sought to understand how SNH burden affects TOO achievement in colorectal cancer.

METHODS:

The National Cancer Database was queried for colorectal cancer patients who underwent resection for stage I-III plus stage IV with liver-only metastases (2010-2019). TOO was defined as R0 resection, AJCC-compliant lymphadenectomy (>12 nodes), no prolonged LOS, no 30-day mortality/readmission, and receipt of stage-appropriate adjuvant chemotherapy.

RESULTS:

Of 487,195 patients, 66.7% achieved TOO. Lower achievement was explained by adequate lymphadenectomy (87.3%), non-prolonged LOS (76.3%), and receipt of adjuvant chemotherapy in stage III (60.3%) and IV (54.1%). Treatment at high burden hospitals (HBH, >10% Medicaid/uninsured) was a predictor of non-TOO (Stage I/II OR 0.83, III OR 0.86, IV OR 0.83; all p < 0.001). Achieving TOO was associated with decreased mortality (Stage I/II HR 0.49, III HR 0.48, IV HR 0.57; all p < 0.001), and HBH treatment was a predictor of mortality (Stage I/II HR 1.09, III HR 1.05, IV HR 1.07; all p < 0.05).

CONCLUSIONS:

Treatment at higher SNH burden hospitals was associated with less frequent TOO achievement and increased mortality. Quality improvement targets include receipt of adjuvant chemotherapy and avoidance of prolonged LOS.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Neoplasias Hepáticas Tipo de estudo: Prognostic_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Neoplasias Hepáticas Tipo de estudo: Prognostic_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Ano de publicação: 2024 Tipo de documento: Article